With a low 5-year survival rate after diagnosis, liver cancer is a major worldwide health concern. The current diagnostic approaches combining ultrasound, CT scans, MRI, and biopsy have the limitation of finding detectable liver cancer when the tumour has already advanced to a specific size, frequently resulting in late-stage diagnoses and dismal clinical treatment outcomes. To this purpose, there has been a great deal of interest in developing highly sensitive and selective biosensors to examine relevant cancer biomarkers in the early stage diagnosis and provide suitable treatment alternatives. Aptamers are a perfect recognition element among the many methods since they can bind to target molecules with great affinity and specificity.
HTML PDFShare this article
Biosensors & Bioelectronics received 6207 citations as per Google Scholar report
